<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01373554</url>
  </required_header>
  <id_info>
    <org_study_id>PMK-N01GI1</org_study_id>
    <nct_id>NCT01373554</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Oltipraz in the Patients With Non-alcoholic Fatty Liver Disease</brief_title>
  <acronym>PMK-N01GI1</acronym>
  <official_title>A Multicenter, Randomized, Double-blind, Placebo-controlled, A Multicenter, Randomized, Double-blind, Placebo-controlled, 3 Parallel Groups, Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Oltipraz in Patients With Non-alcoholic Fatty Liver Disease (Except Liver Cirrhosis)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PharmaKing</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PharmaKing</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dithiolethiones, a novel class of adenosine monophosphate-activated protein kinase (AMPK)
      activators, prevent insulin resistance through AMPK-dependent p70 ribosomal S6 kinase-1
      (S6K1) inhibition. And it is well known that the modulation of S6K1 by oltipraz inhibited the
      development of insulin resistance and hyperglycemia through the AMPK-S6K1 pathway.Also some
      research reported that LXRg (a member of the nuclear hormone receptor)-mediated increases in
      SREBP-1c (the sterol regulatory element-binding protein-1c gene) promote the expression of
      lipogenic genes and enhance fatty acid synthesis and oltipraz inhibits LXRg and SREBP-c.
      Therefore, Oltipraz inhibits fatty acid synthesis through AMPK-S6K1 pathway and LXRg-SREBP-1c
      pathway in liver.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MRS</measure>
    <time_frame>24 weeks</time_frame>
    <description>To evaluate the efficacy of the Oltipraz on change in quantity of liver fat concentration assessed by MRS from baseline to 24 weeks in patients with non-alcoholic fatty liver disease</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>change in ALT, AST and total bilirubin</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in Cholesterol, Triglyceride</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in HOMA-IR</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in BMI</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in NAS</measure>
    <time_frame>24 weeks</time_frame>
    <description>Subjects with liver biopsy:</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Non-alcoholic Fatty Liver Disease</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Oltipraz</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>30mig/bid or 60mg/bid P.O</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oltipraz</intervention_name>
    <description>30mig/bid or 60mg/bid P.O</description>
    <arm_group_label>Oltipraz</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients over 18, under 75 years of age

          -  Patients with non-alcoholic fatty liver disease

        Exclusion Criteria:

          -  Over 2 ratio of AST to ALT

          -  Type 1 diabetes mellitus (insulin-dependent diabetes mellitus)

          -  Disorder in liver function with an exception of non-alcoholic fatty liver (e.g. Virus
             infection, biliary atresia, autoimmune hepatitis and etc.)

          -  Patients who have been taken drugs induced fatty liver for over 3 month within 1 year
             of participation in this study; amiodarone, tamoxifen, methotrexate, tetracyclines,
             glucocorticoids, anabolic steroids, over usual dose of estrogen for hormone
             replacement therapy and valproate

          -  Patients who has been taken any medications that could affect the treatment for
             non-alcoholic steatohepatitis: insulin, insulin sensitizer(metformin,
             thiazolidinedione), high dose of vitamin E, high dose of UDCA, pentoxifylline, SAM-e,
             Betaine, types of Statin, types of fibrate and orlistat

          -  Patients who had a Bariatric surgery less than 6 month prior to the participation in
             the study

          -  Patients who are judged by investigator that participation of the study is difficult
             due to disease as follow; hepatic cirrhosis, Wilson's disease, malignant tumor,
             serious metabolic disease, severe renal disease, severe pulmonary disease, severe
             cardiovascular disease, severe nervous disease/psychiatric disorder, muscle disease
             and etc

          -  Any history of immune disorder which affect the changes in cytokine:

        inflammatory bowel disease, autoimmune thrombocytopenic purpura, system lupus
        erythematosus, autoimmune hemolytic anemia, severe psoriasis, rheumatic arthritis and etc

          -  Patients who have received treatment that may affect liver function within 1 month
             prior to the participation in the study

          -  Patient who has been administered other investigational product within 1 month prior
             to the participation in the study

          -  Patient who is not allowed to get MRS test: pacemaker, shunt and etc

          -  Pregnant or nursing women

          -  Patient who considered ineligible for participation in the study as Investigator's
             judgment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>YoonJun Kim, MD.PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Inje University Ilsan Paik Hospital</name>
      <address>
        <city>Dahwa-dong, Ilsanseo-gu</city>
        <state>Goyang-si, Gyeonggi-do</state>
        <zip>411-706</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NHUS Ilsan Hospital</name>
      <address>
        <city>Ilsan-ro Ilsan-donggu</city>
        <state>Goyang-si</state>
        <zip>410-719</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Daehak-ro Jongno-gu</city>
        <state>Seoul</state>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea University Guro hospital</name>
      <address>
        <city>Gurodong-ro</city>
        <state>Seoul</state>
        <zip>152-703</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boramae Hospital</name>
      <address>
        <city>Sindaebang-dong Dongjak-gu</city>
        <state>Seoul</state>
        <zip>156-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>http://druginfo.nlm.nih.gov/drugportal/ProxyServlet?mergeData=true&amp;objectHandle=DBMaint&amp;APPLICATION_NAME=drugportal&amp;actionHandle=default&amp;nextPage=jsp/drugportal/ResultScreen.jsp&amp;TXTSUPERLISTID=0064224211&amp;QV1=OLTIPRAZ</url>
    <description>Oltipraz</description>
  </link>
  <reference>
    <citation>Kim SG, Kim YM, Choi YH, Lee MG, Choi JY, Han JY, Cho SH, Jang JW, Um SH, Chon CY, Lee DH, Jang JJ, Yu ES, Lee YS. Pharmacokinetics of oltipraz and its major metabolite (RM) in patients with liver fibrosis or cirrhosis: relationship with suppression of circulating TGF-beta1. Clin Pharmacol Ther. 2010 Sep;88(3):360-8. doi: 10.1038/clpt.2010.89. Epub 2010 Jul 21.</citation>
    <PMID>20664537</PMID>
  </reference>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 3, 2011</study_first_submitted>
  <study_first_submitted_qc>June 13, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 15, 2011</study_first_posted>
  <last_update_submitted>December 8, 2013</last_update_submitted>
  <last_update_submitted_qc>December 8, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 10, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oltipraz</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

